Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 4/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 4/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL375222 | 0.87 | CARM1 (0.61) | CARM1PRMT6PIM1EPHX1GLS | |
| SCHEMBL374992 | 0.79 | GLS (0.49) | CARM1PRMT6PIM1DRD4CHRM2 | |
| SCHEMBL2466378 | 0.77 | CARM1 (0.68) | CARM1PRMT6CHRM2CHRM1CHRM3 | |
| SCHEMBL29456931 | 0.77 | CARM1 (0.68) | CARM1PRMT6CHRM2CHRM1CHRM3 | |
| SCHEMBL375045 | 0.75 | GLS (0.57) | CARM1PRMT6PIM1EPHX1GLS | |
| SCHEMBL2106918 | 0.75 | GRIN2B (0.65) | OPRL1 | |
| SCHEMBL8217923 | 0.75 | CARM1 (0.59) | CARM1PRMT6DRD4GLS | |
| SCHEMBL22957905 | 0.74 | CHRM2 (0.66) | CARM1PRMT6CNR1CHRM2CHRM1 | |
| SCHEMBL374832 | 0.73 | BCHE (0.60) | CARM1PRMT6SCN9A | |
| SCHEMBL69474 | 0.73 | BCHE (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623898-B2 | Glycine transporter inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-01-07 | — | — | US | disclosed |
| EP-2409976-A1 | GLYCINE TRANSPORTER INHIBITOR | Taisho Pharmaceutical Co., Ltd. (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010414-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | SLC18A2, SLC1A2, SLC6A1 | CARM1 2663/4885PRMT6 2112/4885CNR1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.